OUR TEAM

Charles Hugh-Jones, M.D., FRCP

Dr. Hugh-Jones is an experienced biotech leader and a board-certified physician who led Volastra Therapeutics as its first CEO from 2020 to 2025. Prior to joining Volastra, he served as the global chief medical officer at Allergan PLC, where he led complex interdisciplinary teams and supported the launch of novel medicines in multiple therapeutic areas. Before Allergan, Dr. Hugh-Jones worked for Pfizer Oncology as their chief medical officer and had medical oversight of all late-stage drug development and commercialization activities. He began his career at Schering AG, Enzon Pharmaceuticals and Sanofi, where he held various positions of increasing responsibility. Dr. Hugh-Jones received his bachelor’s in neuroanatomy, M.D. from the University of London and completed higher specialist training in diagnostic radiology.